Literature DB >> 15615632

Recent advances in experimental modeling of the assembly of tau filaments.

Li-Wen Ko1, Michael DeTure, Naruhiko Sahara, Rifki Chihab, Irving E Vega, Shu-Hui Yen.   

Abstract

Intracellular assembly of microtubule-associated protein tau into filamentous inclusions is central to Alzheimer's disease and related disorders collectively known as tauopathies. Although tau mutations, posttranslational modifications and degradations have been the focus of investigations, the mechanism of tau fibrillogenesis in vivo still remains elusive. Different strategies have been undertaken to generate animal and cellular models for tauopathies. Some are used to study the molecular events leading to the assembly and accumulation of tau filaments, and others to identify potential therapeutic agents that are capable of impeding tauopathy. This review highlights the latest developments in new models and how their utility improves our understanding of the sequence of events leading to human tauopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15615632     DOI: 10.1016/j.bbadis.2004.09.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Taxol and tau overexpression induced calpain-dependent degradation of the microtubule-destabilizing protein SCG10.

Authors:  Irving E Vega; Tadanori Hamano; Josh A Propost; Gabriele Grenningloh; Shu-Hui Yen
Journal:  Exp Neurol       Date:  2006-07-05       Impact factor: 5.330

2.  Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.

Authors:  Shannon N Campbell; Cheng Zhang; Louise Monte; Allyson D Roe; Kenner C Rice; Yvette Taché; Eliezer Masliah; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  Inhibition of Tau aggregation by three Aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde.

Authors:  Smita R Paranjape; Yi-Ming Chiang; James F Sanchez; Ruth Entwistle; Clay C C Wang; Berl R Oakley; T Chris Gamblin
Journal:  Planta Med       Date:  2014-01-10       Impact factor: 3.352

4.  Cytosine beta-D-arabinofuranoside used as a paradigm modifier to increase production of tau aggregates in a cellular model of tauopathy.

Authors:  Li-Wen Ko; Jayanarayan G Kulathingal; Shu-Hui C Yen
Journal:  Neurochem Res       Date:  2006-12-06       Impact factor: 3.996

5.  Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy.

Authors:  Tadanori Hamano; Tania F Gendron; Li-Wen Ko; Shu-Hui Yen
Journal:  Int J Clin Exp Pathol       Date:  2009-06-15

6.  Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes.

Authors:  Alexis Bretteville; Kunie Ando; Antoine Ghestem; Anne Loyens; Séverine Bégard; Jean-Claude Beauvillain; Nicolas Sergeant; Malika Hamdane; Luc Buée
Journal:  PLoS One       Date:  2009-03-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.